CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

NCT06035744 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: CLN-617
DRUG: Pembrolizumab

Sponsor

Cullinan Therapeutics Inc.